Molecular imaging of multiple sclerosis: from the clinical demand to novel radiotracers.
Amyloid
Multiple sclerosis
Neuroinflammation
Positron emission tomography
TSPO
Tumefactive multiple sclerosis
Journal
EJNMMI radiopharmacy and chemistry
ISSN: 2365-421X
Titre abrégé: EJNMMI Radiopharm Chem
Pays: England
ID NLM: 101714628
Informations de publication
Date de publication:
08 Apr 2019
08 Apr 2019
Historique:
received:
21
02
2019
accepted:
21
03
2019
entrez:
30
10
2019
pubmed:
30
10
2019
medline:
30
10
2019
Statut:
epublish
Résumé
Brain PET imaging with different tracers is mainly clinically used in the field of neurodegenerative diseases and brain tumors. In recent years, the potential usefulness of PET has also gained attention in the field of MS. In fact, MS is a complex disease and several processes can be selected as a target for PET imaging. The use of PET with several different tracers has been mainly evaluated in the research setting to investigate disease pathophysiology (i.e. phenotypes, monitoring of progression) or to explore its use a surrogate end-point in clinical trials. We have reviewed PET imaging studies in MS in humans and animal models. Tracers have been grouped according to their pathophysiological targets (ie. tracers for myelin kinetic, neuroinflammation, and neurodegeneration). The emerging clinical indication for brain PET imaging in the differential diagnosis of suspected tumefactive demyelinated plaques as well as the clinical potential provided by PET images in view of the recent introduction of PET/MR technology are also addressed. While several preclinical and fewer clinical studies have shown results, full-scale clinical development programs are needed to translate molecular imaging technologies into a clinical reality that could ideally fit into current precision medicine perspectives.
Sections du résumé
BACKGROUND
BACKGROUND
Brain PET imaging with different tracers is mainly clinically used in the field of neurodegenerative diseases and brain tumors. In recent years, the potential usefulness of PET has also gained attention in the field of MS. In fact, MS is a complex disease and several processes can be selected as a target for PET imaging. The use of PET with several different tracers has been mainly evaluated in the research setting to investigate disease pathophysiology (i.e. phenotypes, monitoring of progression) or to explore its use a surrogate end-point in clinical trials.
RESULTS
RESULTS
We have reviewed PET imaging studies in MS in humans and animal models. Tracers have been grouped according to their pathophysiological targets (ie. tracers for myelin kinetic, neuroinflammation, and neurodegeneration). The emerging clinical indication for brain PET imaging in the differential diagnosis of suspected tumefactive demyelinated plaques as well as the clinical potential provided by PET images in view of the recent introduction of PET/MR technology are also addressed.
CONCLUSION
CONCLUSIONS
While several preclinical and fewer clinical studies have shown results, full-scale clinical development programs are needed to translate molecular imaging technologies into a clinical reality that could ideally fit into current precision medicine perspectives.
Identifiants
pubmed: 31659498
doi: 10.1186/s41181-019-0058-3
pii: 10.1186/s41181-019-0058-3
pmc: PMC6453990
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
6Références
Q J Nucl Med Mol Imaging. 2017 Dec;61(4):345-359
pubmed: 28750494
Nat Immunol. 2013 Nov;14(11):1166-72
pubmed: 24076635
Brain. 2006 Dec;129(Pt 12):3186-95
pubmed: 16766541
Eur J Nucl Med Mol Imaging. 2014 May;41(5):995-1003
pubmed: 24499866
Eur J Nucl Med Mol Imaging. 2019 Feb;46(2):280-287
pubmed: 30343433
J Cereb Blood Flow Metab. 2014 Jun;34(6):989-94
pubmed: 24643083
Eur J Nucl Med Mol Imaging. 2019 Feb;46(2):276-279
pubmed: 30554257
Brain. 2017 Nov 1;140(11):2927-2938
pubmed: 29053775
Mult Scler. 2011 Aug;17(8):931-8
pubmed: 21372113
Org Biomol Chem. 2018 Dec 5;16(47):9171-9184
pubmed: 30462126
Ann Neurol. 1999 Nov;46(5):747-54
pubmed: 10553992
Ann Neurol. 2001 Sep;50(3):389-400
pubmed: 11558796
Neuroimage. 2012 Apr 2;60(2):902-10
pubmed: 22251896
Neurotherapeutics. 2017 Oct;14(4):924-933
pubmed: 28695472
PLoS One. 2015 Mar 27;10(3):e0120754
pubmed: 25816303
Mult Scler Relat Disord. 2017 Jul;15:27-33
pubmed: 28641769
Prog Neurobiol. 2018 Jan;160:82-100
pubmed: 29097192
Mult Scler. 2012 Nov;18(11):1633-5
pubmed: 22419673
Neuroimaging Clin N Am. 2017 May;27(2):277-287
pubmed: 28391786
Neurol Clin Pract. 2017 Feb;7(1):53-64
pubmed: 29849229
J Nucl Cardiol. 2017 Apr;24(2):558-570
pubmed: 26843200
EJNMMI Res. 2013 Apr 24;3(1):30
pubmed: 23618062
Ann N Y Acad Sci. 2007 Dec;1122:23-34
pubmed: 18077562
Eur J Nucl Med Mol Imaging. 2011 Feb;38(2):352-7
pubmed: 21085954
Ann Neurol. 2011 Apr;69(4):673-80
pubmed: 21337603
Mult Scler Relat Disord. 2018 Nov;26:77-84
pubmed: 30237108
EJNMMI Res. 2017 Dec;7(1):31
pubmed: 28374288
Mult Scler. 1997 Feb;3(1):8-17
pubmed: 9160342
BMC Neurol. 2015 Nov 25;15:243
pubmed: 26607782
Acta Neuropathol. 2017 Jan;133(1):13-24
pubmed: 27988845
Mult Scler Relat Disord. 2016 Sep;9:147-9
pubmed: 27645363
Ann Neurol. 2013 Nov;74(5):688-98
pubmed: 23818306
Bioorg Med Chem. 2010 Dec 15;18(24):8592-9
pubmed: 21071233
Clin Med (Lond). 2017 Dec;17(6):530-536
pubmed: 29196354
EJNMMI Res. 2018 Nov 29;8(1):102
pubmed: 30498919
Presse Med. 2015 Apr;44(4 Pt 2):e159-67
pubmed: 25818312
J Nucl Med. 2014 Aug;55(8):1330-5
pubmed: 24914056
J Nucl Med. 2016 Feb;57(2):291-6
pubmed: 26585055
Nucl Med Biol. 2004 Nov;31(8):975-81
pubmed: 15607479
J Nucl Med. 2007 Jan;48(1):158-67
pubmed: 17204713
Biomed Res Int. 2018 Jun 21;2018:3606970
pubmed: 30035121
Lancet. 2017 Dec 2;390(10111):2481-2489
pubmed: 29029896
J Nucl Med. 2017 Sep;58(9):1477-1482
pubmed: 28302760
Glia. 2014 Jul;62(7):1125-41
pubmed: 24692237
Lancet Neurol. 2018 Feb;17(2):162-173
pubmed: 29275977
Arthritis Res Ther. 2013 Mar 01;15(2):R37
pubmed: 23452511
Brain. 2006 Dec;129(Pt 12):3165-72
pubmed: 16921173
EJNMMI Res. 2017 Oct 26;7(1):89
pubmed: 29150726
Oncol Lett. 2015 Sep;10(3):1763-1768
pubmed: 26622747
Neuroimage. 2014 Feb 15;87:395-402
pubmed: 24188813
J Nucl Med. 2011 Jul;52(7):1094-101
pubmed: 21680698
Magn Reson Med. 1994 Jun;31(6):673-7
pubmed: 8057820
Nat Rev Neurosci. 2015 Mar;16(3):147-58
pubmed: 25697158
Bioorg Med Chem. 2014 Oct 1;22(19):5168-81
pubmed: 25216968
Nucl Med Commun. 2017 May;38(5):372-382
pubmed: 28338530
Mult Scler. 2018 May;24(6):739-749
pubmed: 28474977
PLoS One. 2015 Jun 18;10(6):e0129618
pubmed: 26086915
Neuroimage. 1996 Oct;4(2):87-96
pubmed: 9345500
J Neuroimmune Pharmacol. 2014 Sep;9(4):468-82
pubmed: 24809810
Neuro Oncol. 2013 Mar;15(3):341-51
pubmed: 23335162
Neurology. 2012 Aug 7;79(6):523-30
pubmed: 22764258
Mult Scler Relat Disord. 2013 Oct;2(4):362-9
pubmed: 25877847
J Med Chem. 2015 Apr 23;58(8):3471-84
pubmed: 25826109
Eur J Nucl Med Mol Imaging. 2019 Mar;46(3):540-557
pubmed: 30519867
Proc Natl Acad Sci U S A. 2006 Jun 13;103(24):9304-9
pubmed: 16754874
Eur J Med Chem. 2018 Apr 25;150:796-808
pubmed: 29604582
AJNR Am J Neuroradiol. 2016 Mar;37(3):394-401
pubmed: 26564433
Clin Nucl Med. 2018 Sep;43(9):e289-e295
pubmed: 30004939
J Neurol Neurosurg Psychiatry. 2014 Dec;85(12):1396-404
pubmed: 24769473
J Nucl Med. 2014 Jun;55(6):939-44
pubmed: 24711650
Mol Imaging Biol. 2016 Oct;18(5):724-32
pubmed: 26975859
Glia. 2013 Jan;61(1):10-23
pubmed: 22615180
Lancet Neurol. 2006 Jan;5(1):2-3
pubmed: 16361006
Q J Nucl Med Mol Imaging. 2017 Dec;61(4):360-371
pubmed: 28750495
Ann Neurol. 2016 Nov;80(5):776-790
pubmed: 27686563
Glia. 2013 Apr;61(4):453-65
pubmed: 23322421
Lancet Neurol. 2019 Feb;18(2):198-210
pubmed: 30663609
Front Neurol. 2018 Mar 26;9:181
pubmed: 29632509
Molecules. 2018 Nov 02;23(11):null
pubmed: 30400142
Mult Scler Relat Disord. 2017 May;14:72-79
pubmed: 28619436
Mult Scler. 2017 Oct;23(12):1642-1648
pubmed: 29041873
Eur J Neurol. 2011 Feb;18(2):226-31
pubmed: 20636368
Eur J Nucl Med Mol Imaging. 2015 Jun;42(7):1081-92
pubmed: 25833352
Neuroimmunomodulation. 2015;22(6):343-6
pubmed: 25766575
Ann Neurol. 2008 Feb;63(2):254-62
pubmed: 18257039
J Neurosci. 2006 Feb 8;26(6):1880-7
pubmed: 16467537
Nucl Med Biol. 2012 Apr;39(3):389-99
pubmed: 22154685
Curr Opin Neurol. 2015 Jun;28(3):193-205
pubmed: 25887774
J Cereb Blood Flow Metab. 2013 Sep;33(9):1394-401
pubmed: 23695433
Neurobiol Aging. 2014 Nov;35(11):2603-2616
pubmed: 24973119
J Neurol. 2014 Oct;261(10):1902-10
pubmed: 25034274
J Neurol Neurosurg Psychiatry. 2013 Sep;84(9):1047-53
pubmed: 23334629
World Neurosurg. 2018 Nov;119:244-248
pubmed: 30114544
Methods Mol Biol. 2018;1750:203-212
pubmed: 29512074
Neuroimaging Clin N Am. 2017 May;27(2):343-356
pubmed: 28391791
J Neurol Sci. 2008 Jan 15;264(1-2):9-17
pubmed: 17727889
Ann Neurol. 2015 Oct;78(4):554-67
pubmed: 26292991
J Neuroinflammation. 2018 Feb 22;15(1):55
pubmed: 29471880
Mult Scler. 2011 May;17(5):630-3
pubmed: 21177320
Brain. 2019 Jan 1;142(1):133-145
pubmed: 30561514
Neurol Neuroimmunol Neuroinflamm. 2018 Mar 06;5(3):e443
pubmed: 29520366
Int Immunopharmacol. 2011 Mar;11(3):366-72
pubmed: 20955831
Handb Clin Neurol. 2014;122:15-58
pubmed: 24507512
Proc Natl Acad Sci U S A. 2011 Jan 11;108(2):751-6
pubmed: 21177428
Biol Psychiatry. 2016 Jul 1;80(1):62-72
pubmed: 26809249
Neurotherapeutics. 2017 Oct;14(4):894-904
pubmed: 28948533
PLoS One. 2014 Nov 04;9(11):e111598
pubmed: 25369426
J Cereb Blood Flow Metab. 2007 Sep;27(9):1603-15
pubmed: 17311080
J Nucl Med. 2012 Aug;53(8):1269-76
pubmed: 22738927
Lancet Neurol. 2018 May;17(5):467-480
pubmed: 29656742
Sci Rep. 2018 Jan 12;8(1):607
pubmed: 29330383
N Engl J Med. 2018 Jan 11;378(2):169-180
pubmed: 29320652
Brain Res. 2000 Dec 15;886(1-2):108-112
pubmed: 11119692
J Nucl Med. 2014 Jul;55(7):1112-8
pubmed: 24904112
Mult Scler. 2017 Oct;23(11):1469-1478
pubmed: 27903933
N Engl J Med. 2017 Jan 19;376(3):209-220
pubmed: 28002688
J Nucl Med. 2017 Jul;58(7):1132-1139
pubmed: 28280223
N Engl J Med. 2010 Feb 4;362(5):387-401
pubmed: 20089952
Brain. 2018 Aug 1;141(8):2272-2279
pubmed: 30730551
Neurology. 1994 Jun;44(6):1054-9
pubmed: 8208399
Ann Neurol. 2016 May;79(5):726-738
pubmed: 26891452
Mol Imaging Biol. 2013 Aug;15(4):384-90
pubmed: 23508466
Front Neurosci. 2014 Oct 07;8:315
pubmed: 25339862
Oncol Lett. 2016 Mar;11(3):2195-2198
pubmed: 26998148
J Cereb Blood Flow Metab. 2012 Jan;32(1):1-5
pubmed: 22008728
J Cereb Blood Flow Metab. 2017 Dec;37(12):3803-3817
pubmed: 28569617
J Nucl Med. 2012 Jun;53(6):994-1001
pubmed: 22582045
Neurology. 2004 Nov 9;63(9):1579-85
pubmed: 15534239
J Neuroinflammation. 2017 Dec 22;14(1):259
pubmed: 29273052
J Clin Neurosci. 2007 Nov;14(11):1126-9
pubmed: 17890092
Glia. 2010 Sep;58(12):1465-76
pubmed: 20648639
Intern Med. 2015;54(11):1411-4
pubmed: 26027998
Brain Res. 2011 May 16;1390:126-41
pubmed: 21406188
J Neuroimaging. 2013 Jul;23(3):431-6
pubmed: 23279326
Nat Neurosci. 2016 Jul 26;19(8):987-91
pubmed: 27459405
Ann Neurol. 2009 Oct;66(4):460-71
pubmed: 19847908
J Neuroimmune Pharmacol. 2011 Sep;6(3):354-61
pubmed: 20872081
Curr Med Chem. 2018;25(26):3105-3130
pubmed: 28595550
Magn Reson Med. 2016 Aug;76(2):456-65
pubmed: 26331978
ChemMedChem. 2011 Apr 4;6(4):667-77
pubmed: 21280229
Eur J Nucl Med Mol Imaging. 2016 Aug;43(9):1747
pubmed: 27221519